APOB inhibition significantly decreased the risk of lung cancer in ever-smokers [odds ratio (OR) 0.81, 95% confidence interval (CI) 0.70–0.92, p = 0.01] and SCLC (OR 0.70, 95% CI 0.55–0.88, p = 0.014) via ApoB reduction by 1 standard deviation (SD). This evidence concerns the gene APOB and lung carcinoma.